BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pawłowska I, Pawłowski L, Krzyżaniak N, Kocić I. Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals. BioDrugs 2019;33:183-91. [PMID: 30830647 DOI: 10.1007/s40259-019-00341-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Gasteiger C, Gasteiger N, Petrie KJ. Pharmacists' confidence in explaining biosimilars to patients before a nationwide medicine change: A cross-sectional study. Exploratory Research in Clinical and Social Pharmacy 2022;8:100199. [DOI: 10.1016/j.rcsop.2022.100199] [Reference Citation Analysis]
2 Oqal M, Hijazi B, Alqudah A, Al-Smadi A, A Almomani B, Alnajjar R, Abu Ghunaim M, Irshaid M, Husam A. Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan. Int J Clin Pract 2022;2022:8080308. [PMID: 35832802 DOI: 10.1155/2022/8080308] [Reference Citation Analysis]
3 Mohd Sani N, Aziz Z, Panickar R, Kamarulzaman A. Pharmacists' Perspectives of Biosimilars: A Systematic Review. BioDrugs 2022. [PMID: 35776294 DOI: 10.1007/s40259-022-00541-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hu Y, Song Z, Jiang D, Zhuo L, Cheng Y, Zhao R. Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey. Front Pharmacol 2022;13:876503. [PMID: 35721219 DOI: 10.3389/fphar.2022.876503] [Reference Citation Analysis]
5 Memisoglu M, Bilen Ö. A framework for advanced technology medicines from the perspective of community pharmacists; with or without technology. Braz J Pharm Sci 2022;58. [DOI: 10.1590/s2175-97902022e20654] [Reference Citation Analysis]
6 Okoro RN, Hedima EW, Aguiyi-Ikeanyi CN. Knowledge, attitudes, and practices of pharmacists toward biosimilar medicines in Nigeria. J Am Pharm Assoc (2003) 2021:S1544-3191(21)00384-8. [PMID: 34654651 DOI: 10.1016/j.japh.2021.09.014] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Tolonen HM, Falck J, Kurki P, Ruokoniemi P, Hämeen-Anttila K, Shermock KM, Airaksinen M. Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review. BioDrugs 2021. [PMID: 34398421 DOI: 10.1007/s40259-021-00493-8] [Reference Citation Analysis]
8 Ramzan I, Kahlaee R. Knowledge Areas and Competency Standards on Biologic Medicines for Pharmacists and Pharmacy Students. Biologics, Biosimilars, and Biobetters 2020. [DOI: 10.1002/9781119564690.ch15] [Reference Citation Analysis]
9 Halimi V, Daci A, Ancevska Netkovska K, Suturkova L, Babar ZU, Grozdanova A. Clinical and Regulatory Concerns of Biosimilars: A Review of Literature. Int J Environ Res Public Health 2020;17:E5800. [PMID: 32796549 DOI: 10.3390/ijerph17165800] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
10 Więckowski Z, Cardinal Stephan Wyszynski University in Warsaw, Poland, Law and Administration Faculty. Is the Compulsory Licensing Mechanism Guaranteed by TRIPS the Best Remedy to Improve Access to Biological Therapies Worldwide? EEJTR 2019;3:39-52. [DOI: 10.15290/eejtr.2019.03.01.03] [Reference Citation Analysis]